Akoya Biosciences Stock Today

AKYA Stock  USD 3.00  0.11  3.81%   

Performance

8 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Over 63

 
High
 
Low
Quite High
Akoya Biosciences is trading at 3.00 as of the 12th of October 2024, a 3.81 percent increase since the beginning of the trading day. The stock's open price was 2.89. Akoya Biosciences has more than 63 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Akoya Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of September 2024 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
16th of April 2021
Category
Healthcare
Classification
Health Care
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. The company has 49.5 M outstanding shares of which 2.36 M shares are presently shorted by private and institutional investors with about 16.87 trading days to cover. More on Akoya Biosciences

Moving against Akoya Stock

  0.66GH Guardant HealthPairCorr
  0.57VTAK Catheter PrecisionPairCorr
  0.44OM Outset MedicalPairCorr
  0.32VREX Varex Imaging Corp Fiscal Year End 12th of November 2024 PairCorr

Akoya Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentBrian McKelligon
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.360.5358
Way Down
Slightly volatile
Gross Profit Margin0.640.4992
Significantly Up
Very volatile
Total Current Liabilities30.4 M35.3 M
Fairly Down
Slightly volatile
Non Current Liabilities Total77.9 M91.3 M
Fairly Down
Slightly volatile
Total Assets157.2 M180.4 M
Fairly Down
Slightly volatile
Total Current Assets97.8 M121.8 M
Significantly Down
Slightly volatile
Debt Levels
Akoya Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Akoya Biosciences' financial leverage. It provides some insight into what part of Akoya Biosciences' total assets is financed by creditors.
Liquidity
Akoya Biosciences currently holds 85.71 M in liabilities with Debt to Equity (D/E) ratio of 0.62, which is about average as compared to similar companies. Akoya Biosciences has a current ratio of 3.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Akoya Biosciences' use of debt, we should always consider it together with its cash and equity.

Change To Inventory

(6.65 Million)
Akoya Biosciences (AKYA) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Marlborough, MA, United States, 01752 and employs 330 people. Akoya Biosciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 148.5 M. Akoya Biosciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 49.5 M outstanding shares of which 2.36 M shares are presently shorted by private and institutional investors with about 16.87 trading days to cover. Akoya Biosciences currently holds about 87.61 M in cash with (50.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31.
Check Akoya Biosciences Probability Of Bankruptcy
Ownership Allocation
Akoya Biosciences holds a total of 49.5 Million outstanding shares. Over half of Akoya Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Akoya Ownership Details

Akoya Stock Institutional Holders

InstituionRecorded OnShares
Northern Trust Corp2024-06-30
209.7 K
Bridgeway Capital Management, Llc2024-06-30
179.6 K
Charles Schwab Investment Management Inc2024-06-30
175.9 K
Gsa Capital Partners Llp2024-06-30
165.8 K
Osterweis Capital Management Inc2024-06-30
126.1 K
Morgan Stanley - Brokerage Accounts2024-06-30
108.2 K
Bank Of New York Mellon Corp2024-06-30
67.5 K
Squarepoint Ops Llc2024-06-30
65.9 K
Zeliff Wallace Jackson Invst Counsel Inc2024-06-30
46.5 K
Blue Water Life Science Advisors, Llc2024-06-30
4.7 M
Blackrock Inc2024-06-30
1.5 M
View Akoya Biosciences Diagnostics

Akoya Biosciences Historical Income Statement

At present, Akoya Biosciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to about 41.4 K, whereas Net Interest Income is forecasted to decline to (5.4 M). View More Fundamentals

Akoya Stock Against Markets

Akoya Biosciences Corporate Management

Already Invested in Akoya Biosciences?

The danger of trading Akoya Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akoya Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akoya Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akoya Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Revenue Per Share
1.889
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.18)
Return On Equity
(1.28)
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.